| abstract |
A 5-HT 6 receptor antagonist is provided. Novel arylamine compounds having Formula I (wherein the variables are as described in the specification) and pharmaceutically acceptable salts and / or esters thereof; and these compounds and their pharmaceuticals Physiological conditions of the composition, eg, obesity and obesity related diseases such as cardiovascular disease, digestive disease, respiratory disease, cancer and serotonin action such as type II diabetes; and psychological disorders such as schizophrenia Disclosed for use in treatment, modulation and / or prevention in the treatment of [Selection figure] None |